Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Clinical trial NCT05159778 · COMPLETED

Trial details

NCT number: NCT05159778
Sponsor: HiberCell, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Neoplasm of Breast

Start date: 2021-11-09
Primary completion: 2023-03-22
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.